{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:19:33Z","timestamp":1788844773270,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00280-024-04683-3","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T10:07:19Z","timestamp":1723025239000},"page":"535-547","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effect of midostaurin on the pharmacokinetics of P-gp, BCRP, and CYP2D6 substrates: assessing potential drug-drug interactions in healthy participants"],"prefix":"10.1007","volume":"94","author":[{"given":"Romain","family":"Sechaud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gholamreza","family":"Rahmanzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ovidiu","family":"Chiparus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Breitschaft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans D.","family":"Menssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,7]]},"reference":[{"key":"4683_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2147\/OTT.S236740","volume":"16","author":"S Garciaz","year":"2023","unstructured":"Garciaz S, Hospital MA (2023) FMS-like tyrosine kinase 3 inhibitors in the treatment of acute myeloid leukemia: an update on the emerging evidence and safety profile. Onco Targets Ther 16:31\u201345. https:\/\/doi.org\/10.2147\/OTT.S236740","journal-title":"Onco Targets Ther"},{"issue":"9","key":"4683_CR2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1177\/2040620717721459","volume":"8","author":"MM Gallogly","year":"2017","unstructured":"Gallogly MM, Lazarus HM, Cooper BW (2017) Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis. Ther Adv Hematol 8(9):245\u2013261. https:\/\/doi.org\/10.1177\/2040620717721459","journal-title":"Ther Adv Hematol"},{"issue":"4","key":"4683_CR3","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1182\/bloodadvances.2017011080","volume":"2","author":"RM Stone","year":"2018","unstructured":"Stone RM, Manley PW, Larson RA, Capdeville R (2018) Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. Blood Adv 2(4):444\u2013453. https:\/\/doi.org\/10.1182\/bloodadvances.2017011080","journal-title":"Blood Adv"},{"key":"4683_CR4","unstructured":"FDA (2023) RYDAPT\u00ae (midostaurin) capsules, for oral use initial U.S. approval: 2017 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/207997s000lbl.pdf"},{"key":"4683_CR5","unstructured":"EMA (2023, 26\/7\/2023). Rydapt Product Information. Retrieved 28 May 2024 from https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rydapt-epar-product-information_en.pdf"},{"issue":"5","key":"4683_CR6","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1124\/dmd.116.072744","volume":"45","author":"H He","year":"2017","unstructured":"He H, Tran P, Gu H, Tedesco V, Zhang J, Lin W, Gatlik E, Klein K, Heimbach T (2017) Midostaurin, a novel protein kinase inhibitor for the treatment of acute myelogenous leukemia: insights from human absorption, metabolism, and excretion studies of a BDDCS II drug. Drug Metab Dispos 45(5):540\u2013555. https:\/\/doi.org\/10.1124\/dmd.116.072744","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"4683_CR7","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00280-023-04635-3","volume":"93","author":"R Sechaud","year":"2024","unstructured":"Sechaud R, Gu H, Rahmanzadeh G et al (2024) Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants. Cancer Chemother Pharmacol 93(5):439\u2013453. https:\/\/doi.org\/10.1007\/s00280-023-04635-3","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"4683_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00280-022-04448-w","volume":"90","author":"R Sechaud","year":"2022","unstructured":"Sechaud R, Sinclair K, Grosch K, Ouatas T, Pathak D (2022) Evaluation of drug-drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML). Cancer Chemother Pharmacol 90(1):19\u201327. https:\/\/doi.org\/10.1007\/s00280-022-04448-w","journal-title":"Cancer Chemother Pharmacol"},{"key":"4683_CR9","unstructured":"FDA (2020) In vitro drug interaction studies \u2014 Cytochrome P450 enzyme- and transporter-mediated drug interactions guidance for industry. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/in-vitro-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions Accessed on 28 May 2024"},{"issue":"2","key":"4683_CR10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1124\/dmd.117.078006","volume":"46","author":"H Gu","year":"2018","unstructured":"Gu H, Dutreix C, Rebello S, Ouatas T, Wang L, Chun DY, Einolf HJ, He H (2018) Simultaneous physiologically based pharmacokinetic (PBPK) modeling of parent and active metabolites to investigate complex CYP3A4 drug-drug interaction potential: a case example of midostaurin. Drug Metab Dispos 46(2):109\u2013121. https:\/\/doi.org\/10.1124\/dmd.117.078006","journal-title":"Drug Metab Dispos"},{"key":"4683_CR11","unstructured":"FDA (2016) LANOXIN\u00ae (digoxin) tablets for oral use initial U.S. approval: 1954. From https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/020405s013lbl.pdf Accessed on 28 May 2024"},{"key":"4683_CR12","unstructured":"Digoxin SMPC (2022) https:\/\/www.medicines.org.uk\/emc\/product\/5465\/smpc\/print Accessed on 28 May 2024"},{"key":"4683_CR13","unstructured":"FDA (2023) CRESTOR (rosuvastatin) tablets for oral use initial U.S. approval: 2003 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/021366s043s044lbl.pdf Accessed on 28 May 2024"},{"key":"4683_CR14","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.pharmthera.2016.04.010","volume":"164","author":"CP Taylor","year":"2016","unstructured":"Taylor CP, Traynelis SF, Siffert J, Pope LE, Matsumoto RR (2016) Pharmacology of dextromethorphan: relevance to dextromethorphan\/quinidine (Nuedexta\u00ae) clinical use. Pharmacol Ther 164:170\u2013182. https:\/\/doi.org\/10.1016\/j.pharmthera.2016.04.010","journal-title":"Pharmacol Ther"},{"key":"4683_CR15","unstructured":"FDA (2023) Drug development and drug interactions | table of substrates, inhibitors and inducers. https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers"},{"key":"4683_CR16","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1002\/cpt.1435","volume":"105","author":"A Tornio","year":"2019","unstructured":"Tornio A, Filppula AM, Niemi M, Backman JT (2019) Clinical studies on drug\u2013drug interactions involving metabolism and transport: methodology, pitfalls, and interpretation. Clin Pharmacol Ther 105:1345\u20131361. https:\/\/doi.org\/10.1002\/cpt.1435","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"4683_CR17","first-page":"55","volume":"30","author":"LJ Sheffield","year":"2009","unstructured":"Sheffield LJ, Phillimore HE (2009) Clinical use of pharmacogenomic tests in 2009. Clin Biochem Rev 30(2):55\u201365","journal-title":"Clin Biochem Rev"},{"key":"4683_CR18","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/tpj.2010.91","volume":"12","author":"S Mas","year":"2012","unstructured":"Mas S, Gass\u00f2 P, \u00c1lvarez S et al (2012) Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes. Pharmacogenomics J 12:255\u2013259. https:\/\/doi.org\/10.1038\/tpj.2010.91","journal-title":"Pharmacogenomics J"},{"issue":"1","key":"4683_CR19","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/cpt.889","volume":"104","author":"F Storelli","year":"2018","unstructured":"Storelli F, Matthey A, Lenglet S, Thomas A, Desmeules J, Daali Y (2018) Impact of CYP2D6 functional allelic variations on phenoconversion and drug-drug interactions. Clin Pharmacol Ther 104(1):148\u2013157. https:\/\/doi.org\/10.1002\/cpt.889","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"4683_CR20","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/cpt.406","volume":"100","author":"P Stopfer","year":"2016","unstructured":"Stopfer P, Giessmann T, Hohl K et al (2016) Pharmacokinetic evaluation of a drug transporter cocktail consisting of digoxin, furosemide, metformin, and rosuvastatin. Clin Pharmacol Ther 100(3):259\u2013267. https:\/\/doi.org\/10.1002\/cpt.406","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"4683_CR21","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1177\/0091270002042012008","volume":"42","author":"PD Martin","year":"2002","unstructured":"Martin PD, Kemp J, Dane AL, Warwick MJ, Schneck DW (2002) No effect of rosuvastatin on the pharmacokinetics of digoxin in healthy volunteers. J Clin Pharmacol 42(12):1352\u20131357. https:\/\/doi.org\/10.1177\/0091270002042012008","journal-title":"J Clin Pharmacol"},{"key":"4683_CR22","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (2024) ICH Harmonised guideline. M12 Drug Interaction Studies ICH_M12_Step4_Guideline_2024_0521.pdf Adopted 21 May 2024"},{"key":"4683_CR23","unstructured":"Clinical Pharmacogenetics Implementation Consortium (CPIC) (2015) Guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors https:\/\/cpicpgx.org\/guidelines\/"},{"issue":"6","key":"4683_CR24","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s00280-013-2287-6","volume":"72","author":"C Dutreix","year":"2013","unstructured":"Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y (2013) Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers. Cancer Chemother Pharmacol 72(6):1223\u20131234. https:\/\/doi.org\/10.1007\/s00280-013-2287-6","journal-title":"Cancer Chemother Pharmacol"},{"key":"4683_CR25","unstructured":"EMA (2012) Guideline on the investigation of drug interactions. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-drug-interactions-revision-1_en.pdf"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04683-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-024-04683-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04683-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T04:02:59Z","timestamp":1727496179000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-024-04683-3"}},"subtitle":["Brief title: Drug-drug interaction of midostaurin"],"short-title":[],"issued":{"date-parts":[[2024,8,7]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["4683"],"URL":"https:\/\/doi.org\/10.1007\/s00280-024-04683-3","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,7]]},"assertion":[{"value":"2 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"R Sechaud, G Rahmanzadeh, and H Menssen are employees of Novartis Pharma AG, Switzerland. H Gu and O Chiparus, are employees of Novartis Pharmaceuticals Corporation, USA. A Breitschaft is an employee of Parexel International GmbH, Germany.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was performed in accordance with the ethical principles, which have their origin in the Declaration of Helsinki and are consistent with Good Clinical Practice and applicable regulatory requirements. All participants of the study provided written informed consent according to international standards. The study conducted at the Early Phase Clinical Unit of PAREXEL International GmbH in Berlin, Germany. The study protocol was reviewed and approved by the State Office of Health and Social Affairs Ethics Committee of Berlin (Landesamt f\u00fcr Gesundheit und Soziales Ethik-Kommission des Landes Berlin) for PAREXEL International GmbH. The A2121 study was registered under EudraCT number: EudraCT number: 2018-000971-34, and it obtained a favorable opinion from the IEC. The study participants were informed about the study procedures, risks, and benefits of their participation. Informed consent was documented by the investigator.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and informed consent"}}]}}